Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $33.8 million.

  • Summit Therapeutics' Cash from Financing Activities fell 8343.65% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year decrease of 9511.06%. This contributed to the annual value of $381.2 million for FY2024, which is 34065.86% up from last year.
  • Per Summit Therapeutics' latest filing, its Cash from Financing Activities stood at $33.8 million for Q3 2025, which was down 8343.65% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Cash from Financing Activities ranged from a high of $520.1 million in Q4 2022 and a low of -$23.6 million during Q4 2024
  • For the 5-year period, Summit Therapeutics' Cash from Financing Activities averaged around $67.2 million, with its median value being $13.9 million (2021).
  • As far as peak fluctuations go, Summit Therapeutics' Cash from Financing Activities surged by 186313333.33% in 2021, and later crashed by 47767.11% in 2024.
  • Quarter analysis of 5 years shows Summit Therapeutics' Cash from Financing Activities stood at $1.3 million in 2021, then skyrocketed by 41141.87% to $520.1 million in 2022, then tumbled by 98.8% to $6.3 million in 2023, then crashed by 477.67% to -$23.6 million in 2024, then skyrocketed by 243.2% to $33.8 million in 2025.
  • Its Cash from Financing Activities was $33.8 million in Q3 2025, compared to $2.2 million in Q2 2025 and $7.7 million in Q1 2025.